{"title":"CECCY试验的启示:肌钙蛋白应该成为蒽环类药物心脏毒性预防的靶点吗?","authors":"E. Bocchi, D. Belfort, M. Avila","doi":"10.33696/cardiology.2.017","DOIUrl":null,"url":null,"abstract":"Advances in oncology such as better access to health care system, earlier cancer diagnosis and new chemotherapies have led to longer survival of oncologic patients over the last decades [1]. However, this population is vulnerable to cardiovascular drug-related adverse events like cardiomyopathy, which leads to heart failure and impairs survival and quality of life [2,3]. Among different classes of chemotherapeutic agents, anthracyclines (ANT) stand out as the most related to cardiomyopathy, and may affect cancer survivals in 9% of all cases [4].","PeriodicalId":15510,"journal":{"name":"Journal of Clinical Cardiology","volume":"74 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Insights of CECCY Trial: Should Troponin be the Target for Anthracycline Cardiotoxicity Prevention?\",\"authors\":\"E. Bocchi, D. Belfort, M. Avila\",\"doi\":\"10.33696/cardiology.2.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Advances in oncology such as better access to health care system, earlier cancer diagnosis and new chemotherapies have led to longer survival of oncologic patients over the last decades [1]. However, this population is vulnerable to cardiovascular drug-related adverse events like cardiomyopathy, which leads to heart failure and impairs survival and quality of life [2,3]. Among different classes of chemotherapeutic agents, anthracyclines (ANT) stand out as the most related to cardiomyopathy, and may affect cancer survivals in 9% of all cases [4].\",\"PeriodicalId\":15510,\"journal\":{\"name\":\"Journal of Clinical Cardiology\",\"volume\":\"74 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-10-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.33696/cardiology.2.017\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.33696/cardiology.2.017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Insights of CECCY Trial: Should Troponin be the Target for Anthracycline Cardiotoxicity Prevention?
Advances in oncology such as better access to health care system, earlier cancer diagnosis and new chemotherapies have led to longer survival of oncologic patients over the last decades [1]. However, this population is vulnerable to cardiovascular drug-related adverse events like cardiomyopathy, which leads to heart failure and impairs survival and quality of life [2,3]. Among different classes of chemotherapeutic agents, anthracyclines (ANT) stand out as the most related to cardiomyopathy, and may affect cancer survivals in 9% of all cases [4].
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
